JPWO2020210707A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210707A5 JPWO2020210707A5 JP2021559414A JP2021559414A JPWO2020210707A5 JP WO2020210707 A5 JPWO2020210707 A5 JP WO2020210707A5 JP 2021559414 A JP2021559414 A JP 2021559414A JP 2021559414 A JP2021559414 A JP 2021559414A JP WO2020210707 A5 JPWO2020210707 A5 JP WO2020210707A5
- Authority
- JP
- Japan
- Prior art keywords
- mammal
- bay
- methyl
- iwp
- sgc agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025123759A JP2025172729A (ja) | 2019-04-10 | 2025-07-24 | 心血管機能障害の性別依存性処置のための方法及び材料 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832139P | 2019-04-10 | 2019-04-10 | |
| US62/832,139 | 2019-04-10 | ||
| PCT/US2020/027777 WO2020210707A1 (en) | 2019-04-10 | 2020-04-10 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025123759A Division JP2025172729A (ja) | 2019-04-10 | 2025-07-24 | 心血管機能障害の性別依存性処置のための方法及び材料 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526621A JP2022526621A (ja) | 2022-05-25 |
| JPWO2020210707A5 true JPWO2020210707A5 (https=) | 2023-06-05 |
| JP2022526621A5 JP2022526621A5 (https=) | 2023-06-05 |
Family
ID=72752121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559414A Withdrawn JP2022526621A (ja) | 2019-04-10 | 2020-04-10 | 心血管機能障害の性別依存性処置のための方法及び材料 |
| JP2025123759A Pending JP2025172729A (ja) | 2019-04-10 | 2025-07-24 | 心血管機能障害の性別依存性処置のための方法及び材料 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025123759A Pending JP2025172729A (ja) | 2019-04-10 | 2025-07-24 | 心血管機能障害の性別依存性処置のための方法及び材料 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12465605B2 (https=) |
| EP (1) | EP3952992A4 (https=) |
| JP (2) | JP2022526621A (https=) |
| KR (1) | KR20210150495A (https=) |
| CN (1) | CN114144229A (https=) |
| AU (2) | AU2020273183A1 (https=) |
| CA (1) | CA3136550A1 (https=) |
| IL (1) | IL287073A (https=) |
| MX (2) | MX2021012409A (https=) |
| SG (1) | SG11202110533RA (https=) |
| WO (1) | WO2020210707A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117357506A (zh) * | 2023-09-11 | 2024-01-09 | 重庆医科大学国际体外诊断研究院 | 丹酚酸a在治疗钙化性主动脉瓣膜疾病中的用途 |
| CN117969836B (zh) * | 2024-03-29 | 2024-06-04 | 北京市心肺血管疾病研究所 | 基于血浆炎症蛋白构建主动脉瓣钙化狭窄诊断模型及应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR22934E (fr) | 1919-07-19 | 1921-09-06 | Albert Jean Baptiste Hanotelle | Sifflet électro-automoteur perfectionné pour répétition des signaux sur la locomotive |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| WO1998038168A1 (en) | 1997-02-27 | 1998-09-03 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
| EP0977756A1 (en) | 1997-04-25 | 2000-02-09 | Pfizer Limited | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| PL339836A1 (en) | 1998-02-19 | 2001-01-02 | Eisai Co Ltd | Phtalazine compounds and therapeutic agents suitable to treat erection disorders |
| CN1332943C (zh) | 1998-07-08 | 2007-08-22 | 萨诺费－阿文蒂斯德国有限公司 | 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂 |
| GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| CA2406947A1 (en) | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| CA2411008C (en) | 2000-06-07 | 2006-04-11 | Lilly Icos Llc | Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione |
| EP1366049B1 (en) | 2000-06-23 | 2006-06-21 | Lilly Icos LLC | Pirazino¬1'2':1,6|pyrido¬3,4-b|indole derivatives |
| ES2269408T3 (es) | 2000-06-23 | 2007-04-01 | Lilly Icos Llc | Inhibidores de fosfodiesterasa especifica de gmp ciclico. |
| EP1313736B1 (en) | 2000-06-26 | 2005-07-27 | Lilly Icos LLC | Condensed pyrazindione derivatives as inhibitors of pde5 |
| EP1335923B1 (en) | 2000-10-03 | 2006-07-12 | Lilly Icos LLC | Condensed pyridoindole derivatives |
| ATE337320T1 (de) | 2000-11-06 | 2006-09-15 | Lilly Icos Llc | Indolderivate als pde5-inhibitoren |
| HU229938B1 (en) | 2001-05-03 | 2015-01-28 | Hoffmann La Roche | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| US7091207B2 (en) | 2002-05-22 | 2006-08-15 | Virginia Commonwealth University | Method of treating myocardial infarction with PDE-5 inhibitors |
| WO2004037183A2 (en) | 2002-10-22 | 2004-05-06 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
| GB0318094D0 (en) | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
| US20060094744A1 (en) | 2004-09-29 | 2006-05-04 | Maryanoff Cynthia A | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| WO2007050585A2 (en) | 2005-10-24 | 2007-05-03 | The Johns Hopkins University | Use of a nitric oxide synthase modulator for the treatment of cardiac indications |
| EP2302395B1 (en) * | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| GB201114901D0 (en) | 2011-08-26 | 2011-10-12 | King S College London | Vascular treatments |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| EP2938343B1 (en) | 2012-12-21 | 2018-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating calcific aortic valve stenosis |
| KR102456567B1 (ko) | 2013-08-09 | 2022-10-19 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| CN107580495A (zh) | 2015-05-06 | 2018-01-12 | 拜耳制药股份公司 | 单独和与PDE5抑制剂组合的sGC刺激剂、sGC活化剂用于治疗伴随系统性硬化症(SSc)的指溃疡(DU)的用途 |
| JP7057365B2 (ja) | 2016-09-30 | 2022-04-19 | ゼナメッド コーポレーション | ミドドリンの組成物およびその使用方法 |
| EP4620525A3 (en) | 2016-12-14 | 2025-12-03 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
-
2020
- 2020-04-10 WO PCT/US2020/027777 patent/WO2020210707A1/en not_active Ceased
- 2020-04-10 CA CA3136550A patent/CA3136550A1/en active Pending
- 2020-04-10 AU AU2020273183A patent/AU2020273183A1/en not_active Abandoned
- 2020-04-10 JP JP2021559414A patent/JP2022526621A/ja not_active Withdrawn
- 2020-04-10 CN CN202080028080.5A patent/CN114144229A/zh active Pending
- 2020-04-10 SG SG11202110533RA patent/SG11202110533RA/en unknown
- 2020-04-10 MX MX2021012409A patent/MX2021012409A/es unknown
- 2020-04-10 US US17/602,412 patent/US12465605B2/en active Active
- 2020-04-10 KR KR1020217036324A patent/KR20210150495A/ko active Pending
- 2020-04-10 EP EP20788569.0A patent/EP3952992A4/en active Pending
-
2021
- 2021-10-07 IL IL287073A patent/IL287073A/en unknown
- 2021-10-08 MX MX2024010759A patent/MX2024010759A/es unknown
-
2025
- 2025-07-24 JP JP2025123759A patent/JP2025172729A/ja active Pending
- 2025-10-23 AU AU2025256169A patent/AU2025256169A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020140891A (ru) | Производные пиразола в качестве ингибиторов калликреина | |
| CA2534314C (en) | Benzothiazole derivatives for the treatment of diabetes | |
| JP2007505083A5 (https=) | ||
| WO2013173506A2 (en) | Method of treating muscular degradation | |
| JP2016523976A5 (https=) | ||
| US11168073B2 (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| RU2016129953A (ru) | Фармацевтические комбинации | |
| JP2005502643A5 (https=) | ||
| JP2013531028A5 (https=) | ||
| RU2006136881A (ru) | Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2015128025A (ru) | Ингибиторы сомт | |
| JP2009525978A5 (https=) | ||
| RU2017120858A (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина | |
| WO2014179492A1 (en) | Combination therapy for the treatment of arrhythmias or heart failure | |
| RU2008141509A (ru) | Mglur5 модуляторы 1 | |
| JP2011530607A (ja) | 肺動脈高血圧の治療 | |
| US20130303763A1 (en) | Methods and compositions for the treatment of necrotizing enterocolitis | |
| AU2013356294B2 (en) | Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods | |
| JP2011530607A5 (https=) | ||
| JP2009532438A5 (https=) | ||
| KR20170007868A (ko) | Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법 | |
| JP2013511544A (ja) | 過敏性腸症候群を治療するための方法及びアッセイ | |
| HRP20231036T1 (hr) | Upotreba braf inhibitora za liječenje kožnih reakcija |